Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The Gal4-Type Transcription Factor Pro1 Integrates Inputs from Two Different MAPK Cascades to Regulate Development in the Fungal Pathogen Fusarium oxysporum.
J Fungi (Basel). 2022 Nov 24;8(12):1242. doi: 10.3390/jof8121242.
J Fungi (Basel). 2022.
PMID: 36547575
Free PMC article.
Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package.
Tarazona S, Furió-Tarí P, Turrà D, Pietro AD, Nueda MJ, Ferrer A, Conesa A.
Tarazona S, et al. Among authors: pietro ad.
Nucleic Acids Res. 2015 Dec 2;43(21):e140. doi: 10.1093/nar/gkv711. Epub 2015 Jul 16.
Nucleic Acids Res. 2015.
PMID: 26184878
Free PMC article.
Item in Clipboard
Fusarium oxysporum: exploring the molecular arsenal of a vascular wilt fungus.
Pietro AD, Madrid MP, Caracuel Z, Delgado-Jarana J, Roncero MI.
Pietro AD, et al.
Mol Plant Pathol. 2003 Sep 1;4(5):315-25. doi: 10.1046/j.1364-3703.2003.00180.x.
Mol Plant Pathol. 2003.
PMID: 20569392
Item in Clipboard
Components of TOR and MAP kinase signaling control chemotropism and pathogenicity in the fungal pathogen Verticillium dahliae.
Vangalis V, Markakis EA, Knop M, Pietro AD, Typas MA, Papaioannou IA.
Vangalis V, et al. Among authors: pietro ad.
Microbiol Res. 2023 Jun;271:127361. doi: 10.1016/j.micres.2023.127361. Epub 2023 Mar 12.
Microbiol Res. 2023.
PMID: 36921400
Item in Clipboard
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pietro AD, Cantey-Kiser J, Edwards M, Ascierto PA.
Dummer R, et al. Among authors: pietro ad.
Future Oncol. 2023 May;19(16):1091-1098. doi: 10.2217/fon-2022-1258. Epub 2023 Jun 13.
Future Oncol. 2023.
PMID: 37309702
Free article.
Clinical Trial.
Item in Clipboard
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.
Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, McKean M, Santos ES, Brill K, Polli A, Pietro AD, Ascierto PA.
Schadendorf D, et al. Among authors: pietro ad.
Future Oncol. 2022 Jun;18(17):2041-2051. doi: 10.2217/fon-2021-1486. Epub 2022 Mar 11.
Future Oncol. 2022.
PMID: 35272485
Free article.
Item in Clipboard
Make azoles active again: chalcones as potent reversal agents of transporters-mediated resistance in Candida albicans.
Nim S, Baghel P, Tran-Nguyen VK, Peres B, Nguyen KA, Pietro AD, Falson P, Prasad R, Boumendjel A.
Nim S, et al. Among authors: pietro ad.
Future Med Chem. 2018 Sep 1;10(18):2177-2186. doi: 10.4155/fmc-2018-0081. Epub 2018 Jul 25.
Future Med Chem. 2018.
PMID: 30043631
Item in Clipboard
MDR1 causes resistance to the antitumour drug miltefosine.
Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, Pietro AD, Spitaler M, Grunicke H, Hofmann J.
Rybczynska M, et al. Among authors: pietro ad.
Br J Cancer. 2001 May 18;84(10):1405-11. doi: 10.1054/bjoc.2001.1776.
Br J Cancer. 2001.
PMID: 11355955
Free PMC article.
Item in Clipboard
Cite
Cite